# DESCRIPTION

## FIELD OF THE INVENTION

- relate to expression of Myc and/or pTEF-b

## BACKGROUND OF THE INVENTION

- introduce organ damage and regeneration
- describe regenerative potential of organs
- categorize organs by regenerative potential
- discuss heart failure and cardiomyocyte regeneration
- discuss nervous system injuries and regeneration
- introduce genetic regulation of regeneration
- discuss Myc transcription factor and its functions
- describe Myc's role in cell replication and differentiation
- discuss Myc's role in tissue regeneration
- introduce Myc's transcriptional output and target genes
- discuss Myc's recruitment to gene promoters
- introduce need to understand regeneration mechanisms
- discuss need to influence regeneration mechanisms
- introduce present invention's goal

## SUMMARY OF THE INVENTION

- introduce switchable mouse model for Myc expression
- describe three classes of response to Myc activation
- correlate proliferative response to innate regenerative potential
- introduce Myc's role in regenerative biological output
- describe p-TEFb's role in Myc's regenerative output
- introduce increasing Myc and/or p-TEFb expression for regeneration
- provide nucleic acid molecule for Myc and/or p-TEFb
- describe mRNA molecule with modifications
- introduce nucleic acid construct or vector
- describe inducible Myc transcription factor
- introduce cyclin T1 and/or CDK9 encoding nucleic acid sequence
- provide composition with mRNA molecules
- provide composition with vectors
- introduce use of composition as medicament

## DETAILED DESCRIPTION OF THE INVENTION

- define invention scope
- describe conventional techniques used
- define nucleic acid terms
- define gene terms
- describe nucleic acid molecule embodiments
- describe nucleic acid construct embodiments
- describe myc transcription factor embodiments
- describe cyclin T1 embodiments
- describe CDK9 embodiments
- describe RNA molecule embodiments
- describe modified RNA embodiments
- describe cap modification embodiments
- describe tail modification embodiments
- describe nucleoside modification embodiments
- describe UTR modification embodiments
- describe codon optimization embodiments
- describe modified RNA synthesis methods
- describe preferred RNA sequence embodiments
- describe nucleic acid construct embodiments
- describe inducible myc transcription factor embodiments
- describe myc fusion protein embodiments
- describe modified hormone-binding domain embodiments
- describe inducible promoter embodiments
- describe Tet-On or Tet-Off promoter system embodiments
- describe tetracycline-controlled transactivator embodiments
- describe regulatory sequence embodiments
- describe promoter embodiments
- describe constitutive promoter embodiments
- describe CAG promoter embodiments
- describe vector embodiments with multiple nucleic acid sequences
- describe ribosomal skipping sequence embodiments
- describe tRNA sequence embodiments
- describe linker sequence embodiments
- describe UTR embodiments
- describe cyclin T1 protein embodiments
- describe CDK9 protein embodiments
- describe terminator sequence embodiments
- describe viral vector embodiments
- define non-viral vector
- introduce transfection techniques
- describe chemical transfection
- describe physical transfection
- describe bactofection
- introduce RNA molecule
- describe bicistronic RNA
- introduce host cell
- describe method of increasing cell proliferation
- define increase in cell proliferation
- describe method of increasing organ size
- define increase in organ size
- introduce use of vector or mRNA molecule
- describe host cell or cell
- introduce transgenic organism
- describe transient transformation
- describe stable transformation
- introduce organism obtained or obtainable
- describe composition comprising vectors
- describe composition comprising mRNA molecules
- introduce composition comprising bi or polycistronic RNA molecule
- describe pharmaceutically acceptable carrier
- introduce vector, mRNA molecule or composition for use as medicament
- introduce vector, mRNA molecule or composition for use in treatment
- describe condition characterised by loss of cells or cell death
- describe heart disease
- describe CNS or brain disease
- introduce method of therapy
- describe therapeutically effective amount
- introduce ectopic expression of myc and/or P-TEFb
- describe administration of steroid or thyroid
- describe time scale for administration of steroid or thyroid
- introduce variant or functional variant
- describe alterations in nucleic acid sequence
- describe alterations in ribonucleic acid sequence
- describe alterations in amino acid sequence
- introduce administration of vector or mRNA molecule
- describe physical disturbance
- describe generation of mRNA endocytosis
- describe administration of external stimuli
- describe pharmaceutical compositions

### Example I

- introduce Myc transcription factor
- describe Myc function
- explain P-TEFb regulation
- discuss Max and Mxd family
- summarize Myc pleiotropy
- motivate understanding tissue-specific Myc responses
- introduce mouse model for switchable Myc expression
- describe Myc target gene binding and expression analysis
- explain limitations of global RNA amplification
- introduce results section
- describe R26CAG-LSL-c-MycERT2 mouse strain
- explain MycERT2 expression levels
- introduce allelic series of MycERT2 expression
- describe Western blot analysis
- rule out Rosa26 promoter modulation
- describe proliferative responses to Myc activation
- categorize tissues by proliferative response
- discuss Mxd protein expression
- introduce ChIP-sequencing analysis
- describe Myc target binding sites
- analyze motif enrichment and gene ontology
- discuss tissue-specific Myc binding sites
- conclude on chromatin accessibility and transcriptional control
- introduce Myc binding to target genes
- investigate mechanisms limiting proliferative output
- determine transcriptional output in various tissues
- analyze differentially expressed genes
- compare DEGs in different tissues
- identify common Myc-regulated processes
- analyze Myc repressed genes
- identify tissue-specific genes down-regulated by Myc
- correlate DEG numbers with proliferative response
- analyze transcriptional response to Myc activation
- identify limitations of Myc transcriptional output
- propose insufficiency of transcriptional co-factors
- analyze expression levels of P-TEFb components
- identify negative regulators of P-TEFb
- determine if P-TEFb is limiting Myc-driven transcription
- overexpress Cyclin T1 in adult cardiomyocytes
- analyze effect of Cyclin T1 overexpression on Myc target genes
- propose Larp7 as an alternative target for therapy
- describe method of therapy using CRISPR
- analyze Myc-dependent transcriptional responsiveness in juvenile heart tissue
- determine extent of Myc-dependent transcriptional activation
- analyze global transcriptional response in juvenile heart
- confirm Myc-induced cardiomyocyte proliferation
- restrict expression of MycERT2 to cardiomyocytes
- analyze effect of MycERT2 activation on cardiomyocyte proliferation
- confirm cytokinesis using transmission electron micrographs
- test if increasing P-TEFb activity enables Myc transcriptional activation
- illustrate that Myc transcriptional activity can be facilitated in adult cardiomyocytes

## DISCUSSION

- introduce Myc's role in cell proliferation and tissue regeneration
- describe limitations of past studies on Myc
- present a unique mouse model for studying Myc activation
- detail features of the mouse model
- explain the use of the ZP3 promoter for ubiquitous MycERT2 expression
- describe the comparison of Myc's impact on different adult mouse tissues
- identify three classes of response to Myc activation
- characterize tissues with high endogenous Myc levels and proliferation
- describe tissues with low endogenous Myc levels and facultative regeneration
- describe tissues with low endogenous Myc levels and no regenerative potential
- correlate proliferative response to Myc with innate regenerative potential
- discuss Myc's relationship with Mxd proteins
- analyze ChIP-seq data on Myc binding in responsive and non-responsive tissues
- show that tissue non-responsiveness is not due to Myc's failure to access chromatin targets
- identify common and tissue-specific Myc-bound promoter regions
- note the presence of chromatin marks indicative of open chromatin
- describe the repression of differentiation-specific genes by Myc
- propose a hypothetical explanation for the suppression of differentiation by Myc
- correlate responsiveness to Myc with levels of basal transcription factors
- describe the adult mammalian heart as a non-responsive tissue
- discuss the regulation of P-TEFb during mammalian cardiac development
- show that oncogenic Ras signaling increases Cyclin T1 in the heart
- describe the difficulty of re-establishing regenerative proliferation in the adult heart
- show that enforced ectopic Myc expression extends the window of neonatal cardiomyocyte proliferation
- demonstrate that increased P-TEFb activity supports Myc-dependent transcription and proliferation in the adult heart
- discuss the implications of the study's findings for cardiac regeneration
- summarize the study's conclusions on tissue regenerative capacity and Myc responsiveness

### Example II

- describe the non-regenerative features of the adult mouse brain and kidney
- show that enforced ectopic Myc expression can extend the window of neonatal proliferation in the brain and kidney

